Analysis of lncRNA UCA1-related Downstream Pathways and Molecules of Cisplatin Resistance in Lung Adenocarcinoma

Journal of Clinical Laboratory Analysis - United States
doi 10.1002/jcla.23312
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2014English

CLDN18.1 Attenuates Malignancy and Related Signaling Pathways of Lung Adenocarcinoma in Vivo and in Vitro

International Journal of Cancer
Cancer ResearchOncology
2018English

The Prognostic Value and Mechanisms of lncRNA UCA1 in Human Cancer

Cancer Management and Research
Oncology
2019English

Β-Catenin Signaling Pathway Regulates Cisplatin Resistance in Lung Adenocarcinoma Cells by Upregulating BCL-Xl

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2016English

Integrated TCGA Analysis Implicates lncRNA CTB-193M12.5 as a Prognostic Factor in Lung Adenocarcinoma

Cancer Cell International
Cancer ResearchOncologyGenetics
2018English

LncRNA TATDN1 Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Through TATDN1/miR-451/TRIM66 Axis

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

Inhibitor of DNA Binding 3 Reverses Cisplatin Resistance in Human Lung Adenocarcinoma Cells by Regulating the PI3K/Akt Pathway

Oncology Letters
Cancer ResearchOncology
2018English

Integrated Analysis of Long Non-Coding RNA‑associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Lung Adenocarcinoma

International Journal of Oncology
Cancer ResearchOncology
2016English

lncRNA LOC100132354 Promotes Angiogenesis Through VEGFA/VEGFR2 Signaling Pathway in Lung Adenocarcinoma

Cancer Management and Research
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy